Buscar resultados de ensayos clínicos
Primary Biliary Cholangitis - 29 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid Condición: Primary Biliary Cirrhosis Fecha: 2011-07-07 Intervenciones:
|
Active, not recruiting |
Nombre del estudio: The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland Condición: Primary Biliary Cirrhosis Fecha: 2016-07-25 |
Completed |
Nombre del estudio: Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis Condición: Primary Biliary Cirrhosis Fecha: 2008-12-08 Intervenciones:
|
Completed |
Nombre del estudio: Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis Condición: Primary Biliary Cirrhosis Fecha: 2015-09-21 Intervenciones: Dietary Supplement: S-adenosyl-L-methionine Patients will be treated with S-adenosyl-L-methionine, table |
Completed |
Nombre del estudio: High-protein High-fiber Diet in Patients With Primary Biliary Cirrhosis Condición: Primary Biliary Cirrhosis Fecha: 2012-05-17 Intervenciones: Dietary Supplement: High protein high fiber diet A personalized high protein high fiber dietary plan wil |
NOT_YET_RECRUITING |
Nombre del estudio: CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis) Condición: Fecha: 2024-06-10 Intervenciones: Oral QD |
RECRUITING |
Nombre del estudio: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis Condición: Primary Biliary Cholangitis Fecha: 2024-06-10 Intervenciones: Seladelpar 10 mg one capsule daily for up to 36 months. |
RECRUITING |
Nombre del estudio: A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis Condición: Primary Biliary Cholangitis (PBC) Fecha: 2024-06-10 Intervenciones: Duration: up to an estimated 84-month (7-year) double-blind treatment period during which elafibranor 80 mg tablet will be administered once daily |
RECRUITING |
Nombre del estudio: IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) Condición: Primary Biliary Cholangitis Fecha: 2024-06-10 Intervenciones: Seladelpar 10 mg one capsule daily for up to 52 weeks |